University of Texas System

Surface Oncology, Inc.

Nadthakarn Boland

Bianka Prinz

Dongxing Zha

Michael A Curran

Carlo Toniatti

Ashvin R Jaiswal

Kui Shin Voo

Kevin Schutz

John Bukowski

Marisella Panduro Sicheva

Jennifer Symonds

James Mohan

Eric Krauland

The present disclosure is directed to antibodies binding to PD-L2 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L2.

Human PD-L2 antibodies and methods of use therefor

The present disclosure is directed to antibodies binding to PD-L1 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1.

Human PD-L1 antibodies and methods of use therefor

The invention provides anti-CD112R antibody compositions and their use in treating cancer.

Anti-CD112R compositions and methods

The present disclosure is directed to bispecific antibodies which bind to both PD-L1 and PD-L2, and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1, PD-L2, or both.

Dual specificity antibodies to human PD-L1 and PD-L2 and methods of use therefor

Growing community of inventors

Lebanon, NH, United States of America

Nadthakarn Boland